But there is an ambiguity in terms of PD-L1 expression being a suitable marker for PD-1/PD-L1 antibodies treatment for advanced NSCLC compared with docetaxel in the second-line treatment. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.